Lixisenatide reduces postprandial hyperglycaemia via gastrostatic and insulinotropic effects

BACKGROUND: Lixisenatide is a once‐daily, prandial, short‐acting glucagon‐like peptide‐1 receptor agonist. Its main antidiabetic effect is to delay gastric emptying to control postprandial plasma glucose excursions. The dose–response relationship of the integrated insulinotropic and gastrostatic res...

Descripción completa

Detalles Bibliográficos
Autores principales: Becker, Reinhard H. A., Stechl, Jens, Steinstraesser, Axel, Golor, Georg, Pellissier, Franck
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2015
Materias:
Research Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744661/
https://www.ncbi.nlm.nih.gov/pubmed/25773712
http://dx.doi.org/10.1002/dmrr.2647

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4744661/
https://www.ncbi.nlm.nih.gov/pubmed/25773712
http://dx.doi.org/10.1002/dmrr.2647

Ejemplares similares